Abstract

BackgroundLack of reliable and valid measures of disease activity and clinical response in patients with CTD-ILD makes clinical trial design difficult. From a multi-tiered investigation to develop consensus on provisional...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call